Evusheld Interactions
Showing entire list of all interactions, including brand names and combination drugs.
Go back to interactions summary
Medications known to interact with Evusheld
P
- Pfizer-BioNTech COVID-10 (6m-4y) Vaccine PF (sars-cov-2 mrna (tozinameran 6m-4y) vaccine)
- Pfizer-BioNTech COVID-19 (12y+) Bivalent Booster Vaccine PF (sars-cov-2 (covid-19) mrna (tozinameran 12y+) bivalent booster vaccine)
- Pfizer-BioNTech COVID-19 (12y+) Bivalent Vaccine PF (sars-cov-2 (covid-19) mrna(tozinameran12y+) bivalent vaccine)
- Pfizer-BioNTech COVID-19 (2023-2024) Vaccine PF (cvx 308) (sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 308))
- Pfizer-BioNTech COVID-19 (2023-2024) Vaccine PF (cvx 310) (sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 310))
- Pfizer-BioNTech COVID-19 (5y-11y) Bivalent Booster Vaccine PF (sars-cov-2 (covid-19) mrna (tozinameran 5y-11y) bivalent booster vaccine)
- Pfizer-BioNTech COVID-19 (5y-11y) Bivalent Vaccine PF (sars-cov-2(covid-19)mrna(tozinameran 5y-11y)bivalent vaccine)
- Pfizer-BioNTech COVID-19 (5y-11y) Vaccine PF (sars-cov-2 mrna (tozinameran 5y-11y) vaccine)
- Pfizer-BioNTech COVID-19 (6m-4y) Bivalent Booster Vaccine PF (sars-cov-2 (covid-19) mrna (tozinameran 6m-4y) bivalent booster vaccine)
- Pfizer-BioNTech COVID-19 (6m-4y) Bivalent Vaccine PF (sars-cov-2 (covid-19) mrna (tozinameran 6m-4y) bivalent vaccine)
- Pfizer-BioNTech COVID-19 (6m-4y) Vaccine PF (sars-cov-2 mrna (tozinameran 6m-4y) vaccine)
- Pfizer-BioNTech COVID-19 Vaccine (Do Not Dilute) (sars-cov-2 mrna (tozinameran-tris-sucrose) vaccine)
- Pfizer-BioNTech COVID-19 Vaccine (sars-cov-2 mrna (tozinameran) vaccine)
More about Evusheld (cilgavimab / tixagevimab)
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.